S100A4 and cholangiocarcinoma: Furthermore, it has been reported that nuclear expression of S100A4 protein is a biomarker for predicting increased invasiveness of cholangiocarcinoma and the phenomenon can be inhibited by using low-dose paclitaxel for targeting of S100A4 nuclear import [113].